Article Text

Download PDFPDF
Vertebrobasilar atherosclerotic disease: is it time to revisit angioplasty?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors SA-H: conception and design, drafting; final approval; accountable for content. AHS, TNT, HW, SP: design, revision; final approval; accountable for content. CPD: conception, revision; final approval; accountable for content. FTC: conception and design, revision; final approval; accountable for content.

  • Competing interests SA-H—grant funding: NIH/NINDS (NS 059745); material research support (no direct funds): VasSol, Inc. AHS—consultant: Codman, Medtronic, GuidePoint Global Consulting, Penumbra, Stryker, Microvention, W.L. Gore Associates, Three Rivers Medical, Inc, Corindus, Inc, Amnis Therapeutics, Ltd, CereVasc, LLC, Pulsar Vascular, The Stroke Project, Inc, Cerebrotech Medical Systems, Inc, Rapid Medical, Neuravi, Silk Road Medical, Rebound Medical; Financial interest: StimSox, Valor Medical, NeuroTechnology Investors, Cardinal, Medina Medical Systems, Buffalo Technology Partners, Inc, International Medical Distribution Partners; National Steering Committee: 3D Separator Trial, SWIFT PRIME and SWIFT DIRECT Trials, CONFIDENCE Study, LARGE Trial, POSITIVE Trial, COMPASS Trial, INVEST Trial; board membership: Intersocietal Accreditation Committee. SP—grant funding: NIH/NINDS (NS 084288). CPD—STRATIS trial PI, Medtronic; 3D Separator DSMB, Penumbra. FTC—shareholder: VasSol, Inc.

  • Provenance and peer review Not commissioned; externally peer reviewed.